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Identification of Map4k4 as a Novel Suppressor of Skeletal Muscle
Differentiation
Mengxi Wang, Shinya U. Amano, Rachel J. Roth Flach, Anil Chawla, Myriam Aouadi, Michael P. Czech
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
Myoblast differentiation intomaturemyotubes is a critical step in the development and repair of human skeletalmuscle.Herewe show
that small interferingRNA (siRNA)-based silencing of the Ste20-likemitogen-activated protein 4 kinase 4 (Map4k4) inC2C12myo-
blastsmarkedly enhances expression ofmyogenic differentiation genes,myoblast fusion, andmyotube diameter. In contrast, adenovi-
rus-mediated expression of nativeMap4k4 inC2C12 cells attenuates each of these processes, indicating thatMap4k4 is a negative regu-
lator ofmyogenic differentiation andhypertrophy. Expression of aMap4k4 kinase-inactivemutant enhancesmyotube formation,
suggesting that the kinase activity ofMap4k4 is essential for its inhibition ofmuscle differentiation.Map4k4 regulation ofmyogenesis
is unlikely to bemediated by classicmitogen-activated protein kinase (MAPK) signaling pathways, because no significant difference in
phosphorylation of extracellular signal-regulated kinase (ERK), p38, or c-JunN-terminal kinase (JNK) is observed inMap4k4-silenced
cells. Furthermore, silencing of these otherMAPKs does not result in a hypertrophicmyotube phenotype like that seenwithMap4k4
depletion.Uniquely,Map4k4 silencing upregulates the expression of themyogenic regulatory factorMyf5, whose depletion inhibits
myogenesis. Furthermore,Myf5 is required for enhancement ofmyotube formation inMap4k4-silenced cells, whileMyf5 overexpres-
sion rescuesMap4k4-mediated inhibition ofmyogenic differentiation. These results demonstrate thatMap4k4 is a novel suppressor of
skeletalmuscle differentiation, acting through aMyf5-dependentmechanism.
Skeletalmuscle differentiation is a highly coordinatedmultistepprocess in which mononucleated myoblasts first withdraw
from the cell cycle in response to extracellular cues, then differen-
tiate into postmitotic myocytes (early differentiation), and subse-
quently fuse into multinucleated myotubes (late differentiation)
which finally bundle to form mature muscle fibers (terminal dif-
ferentiation). This process is elaborately controlled by activation
of Myf5, MyoD, myogenin, andMRF4, four myogenic regulatory
factors (MRFs) belonging to a family of basic helix-loop-helix
transcription factors. Duringmyogenesis, MRFs are activated and
operate in concert with other transcriptional regulators, such as
myocyte enhancer factor 2 (MEF2), in a coordinated manner to
regulate the transcription of muscle-specific genes, including
those formyosin heavy chain (MyHC) andmuscle creatine kinase
(MCK) (1–3). Previous studies have confirmed Myf5 and MyoD
as muscle determination factors that are expressed mainly in un-
differentiatedmyoblasts and differentiatingmyocytes, whilemyo-
genin is activated in early differentiation (4). MRF4 has been
shown to be expressed transiently during somitogenesis and later
fiber maturation (5), playing roles in myogenic lineage commit-
ment (6) as well as myoblast fusion and differentiation (7, 8).
Mitogen-activated protein kinases (MAPKs) are components
of serine/threonine protein kinase cascades that respond to extra-
cellular stimuli and regulate essential cellular functions, such as
proliferation (9), differentiation (10–12), and apoptosis (13). The
MAPK family is categorized into three main groups, i.e., p38
stress-activated protein kinase, c-Jun N-terminal kinase (JNK),
and extracellular signal-regulated protein kinase (ERK) (14), all of
which have been demonstrated to be involved inmammalian skel-
etalmyogenesis (15, 16). The exploration of newupstreamkinases
that modulate the downstream effector MAPKs identified mito-
gen-activated protein kinase kinase kinase kinase4 (MAP4K4), a
serine/threonine protein kinase that belongs to the germinal-cen-
ter kinase GCK-IV group of Saccharomyces cerevisiae sterile 20
protein (Ste20) kinases (17).Map4k4may activate the JNK signal-
ing pathway in some cell types and mediate cancer cell prolifera-
tion, apoptosis, and motility (18, 19). It was found to play an
essential role in development (20), and it has been shown to be
critical formesodermmigration during gastrulation by acting up-
stream of p38 MAPK (21). In an RNA interference (RNAi)-based
screen for regulators of adipocyte function, we discovered that
Map4k4 downregulated expression of peroxisome proliferator-
activated receptor  (PPAR), a transcription factor that is essen-
tial for adipocyte differentiation and function (22). Cell size, in-
sulin-mediated glucose transport, and triglyceride content were
found to be increased significantly uponMap4k4 silencing in cul-
tured adipocytes (23), indicating that Map4k4 is a negative regu-
lator of insulin-stimulated lipogenesis and adipose hypertrophy.
More recently, it was found that Map4k4 also functions in
muscle to impair insulin sensitivity. Map4k4 gene silencing in
primary human skeletal muscle cells prevented tumor necrosis
factor alpha (TNF-)-induced insulin resistance (24). However,
the role ofMap4k4 in skeletal myogenesis has not been addressed.
In the present study, we used C2C12 murine myoblasts to inves-
tigate the function ofMap4k4 inmyogenic processes.We demon-
strate that Map4k4 acts upstream of Myf5 as a negative regulator
of skeletal muscle differentiation.
MATERIALS AND METHODS
Molecular biology. A mouse Myf5 clone (GenBank accession number
NM_008656)was purchased fromOpenBiosystems. The coding region of
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the Myf5 gene was PCR amplified and cloned into a pCMV plasmid car-
rying three N-terminal hemagglutinin (HA) tags (pCMV-3HA) to create
anN-terminallyHA-taggedMyf5 construct. Primers used to amplify PCR
fragments of the Myf5 coding region were as follows: for the 5= fragment,
CGATCGCCACGCGTATCTCGAGCTATGGACATGACGGACGGCT
GCCAGTTCTCCCCT; and for the 3= fragment, GCGTACGGATCCGT
CGACTCATAATACGTGATAGATAAGTCTGGAGCTGGAGGGTCC.
Cell culture and transfection. Mouse C2C12 myoblasts (American
Type Culture Collection) were cultured in growthmedium (GM) consist-
ing of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and 1% penicillin-streptomycin at 37°C with 5%
CO2. To induce differentiation, 95% confluent cells were placed in a dif-
ferentiation medium (DM) consisting of DMEM with 2% horse serum.
Multinucleated myotubes were evident after 3 days of differentiation. For
small interferingRNA (siRNA) transfection,C2C12myoblasts cultured in
growth medium were transfected with 50 pmol siRNA by use of Lipo-
fectamine RNAiMAX (Invitrogen) according to the manufacturer’s in-
structions for reverse transfection. Twenty-four hours later, cells were
switched to DM and cultured for the indicated times before harvest. To
transfect siRNA into differentiated myotubes, siRNA-endoporter com-
plexes were used as described previously (25). Briefly, 50 pmol of siRNA
was incubated with 2.5 nmol of endoporter (Gene Tools) in phosphate-
buffered saline (PBS) for 15 min and then added to cells. All siRNAs were
purchased from Dharmacon (Lafayette, CO). For plasmid transfection,
GM-cultured C2C12myoblasts were transfected with 2g of plasmids by
use of Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions for reverse transfection. Twenty-four hours later, cells were
switched to DM and cultured for the indicated times before harvest.
Adenovirus infection. C2C12 myoblasts were grown until 90% con-
fluence and were then infected with a green fluorescent protein (GFP)-
expressing control virus, wild-type Map4k4-expressing virus, or Map4k4
D152N-expressing virus at a dose of 104 virus particles per cell for 18 h in
GM before differentiation. At 72 h postdifferentiation, cells were fixed for
immunofluorescence or harvested for Western blotting. All adenoviruses
were gifts from Diane L. Barber (Department of Cell and Tissue Biology,
University of California, San Francisco, CA).
Myotube analysis. Myotube nuclei were counted in approximately
100 randomly chosen MyHC-positive cells containing three or more nu-
clei. Myotubes were categorized into three groups (3 to 6 nuclei, 7 to 15
nuclei, and15 nuclei per myotube) and were expressed as a percentage
of the total myotube number. The fusion index was calculated as the ratio
of nuclei inMyHC-positive myotubes to the total number of nuclei in the
field for five random fields. To analyze myotube diameter, five fields were
chosen randomly, and three myotubes were measured per field. The av-
erage diameter per myotube was calculated as themean of three measure-
ments taken along the long axis of the myotube.
Isolation of mouse satellite cells. Satellite cells were isolated from 6-
to 8-week-oldC57B6/Jmice by fluorescence-activated cell sorting (FACS)
as described previously (26). Briefly, skeletal muscles were digested with
collagenase B (10 mg/ml; Roche) and dispase II (2.4 U/ml; Roche) and
then filtered successively through 250-, 100, and 40-m nylon meshes.
The resultingmononuclear cells were incubated with anti-mouse integrin
7 clone 3C12 (MBL) and biotin anti-mouse CD34 (eBioscience) anti-
bodies for 20 min and then stained with Hoechst 33258 (Sigma) and with
phycoerythrin (PE)–anti-mouse CD11b (eBiosciences), PE–anti-mouse
CD45 (eBiosciences), PE–anti-mouse Ly-6A-E (Sca1; BD Bioscience),
PE–anti-rat CD31 (BD Bioscience), and streptavidin-allophycocyanin
(APC)-Cy7 (BD Bioscience) antibodies. Integrin 7 CD34 CD31
CD11b CD45 Sca1 cells were considered satellite cells and were
sorted by a BD FACS Aria II flow cytometer.
Western blotting. Cells were solubilized with ice-cold lysis buffer (20
mMHEPES, pH 7.2, 100 mMNaCl, 1 mM EDTA, 100 mM phenylmeth-
ylsulfonyl fluoride [PMSF], 0.01% Triton X-100, 1% SDS, and Halt pro-
tease and phosphatase inhibitor cocktail [Thermo Scientific]), and pro-
tein concentrations were assessed by bicinchoninic acid (BCA) assay
(Thermo Scientific). Equal amounts of protein were loaded onto 8.5%
SDS-polyacrylamide gels and transferred to nitrocellulose membranes.
The following antibodies were used: anti-Map4k4 (Bethyl), anti-Myf5
(sc-20; Santa Cruz), anti-MyoD (BD Biosciences), anti-Mef2C (Cell Sig-
naling), antimyogenin (F5D; Developmental Studies Hybridoma Bank
[DSHB], University of Iowa), anti-sarcomeric myosin heavy chain
(MHC) (MF20; DSHB, University of Iowa), anti-phospho-p38 (Cell Sig-
naling), anti-total p38 (Cell Signaling), anti-phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204) (Cell Signaling), anti-p44/42 MAPK (Erk1/2)
(Santa Cruz), anti-phospho-SAPK/JNK (Thr183/Tyr185) (Cell Signal-
ing), and anti-SAPK/JNK (Cell Signaling).
Immunofluorescence microscopy. Cells grown on glass coverslips
were fixed with 4% formaldehyde and blocked in PBS containing 2% goat
serum (Invitrogen), 1% bovine serum albumin (Sigma), 0.1% Tween 20,
and 0.05% Triton X-100 (American Bioanalytical) for 1 h at room tem-
perature. The cells were then incubated with the MF20 monoclonal anti-
body (MAb) against MHC (1:40; DSHB) for 2.5 h and subsequently with
an Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary antibody
(1:200; Invitrogen) for 1 h at room temperature. Cells weremounted with
ProLong Gold antifade reagent with DAPI (4=,6-diamidino-2-phenylin-
dole; Invitrogen). Images were obtained using a Zeiss Axiovert 200 in-
verted microscope equipped with a Zeiss AxioCam HR charge-coupled
device (CCD) camera.
Creatine kinase activity assay.Cells were lysed in ice-cold lysis buffer
(20 mM HEPES, pH 7.2, 100 mM NaCl, 1 mM EDTA, 100 mM PMSF,
0.01% Triton X-100, and protease and phosphatase inhibitor cocktail).
Lysates were centrifuged at 14,000 g for 10 min at 4°C, and the super-
natants were used immediately for creatine kinase (CK) activity assay. CK
activity was measured using a spectrophotomety-based kit (Stanbio Lab-
oratory, Boerne, TX) according to the manufacturer’s instructions. Spe-
cific CK activity was calculated by normalization to the total protein con-
tent.
Map4k4 kinase activity assay. Cells were solubilized with ice-cold
lysis buffer (50mMTris, pH 7.4, 100mMNaCl, 5mMEDTA, 1%NP-40,
0.1% deoxycholic acid, and protease and phosphatase inhibitor cocktail).
Cell lysates were immunoprecipitated with anti-Map4k4 antibody
(Bethyl). Myelin basic protein (MBP) (1 g) and 10 Ci of [-32P]ATP
were added to the immunoprecipitates and incubated for 30 min at 30°C
in kinase buffer (20 mM HEPES, 10 nM MgCl2, 1 mM dithiothreitol
[DTT], and protease and phosphatase inhibitor cocktail). Samples were
separated by 12%SDS-PAGE and visualized by autoradiography.Map4k4
kinase activities were determined by normalizing the radioactivity of 32P-
labeled MBP to the amount of immunoprecipitated Map4k4 protein de-
tected by Western blotting.
Isolation of RNAandRT-PCR.RNA isolationwas performed accord-
ing to the TRIzol reagent protocol (Invitrogen). cDNA was synthesized
from1.5g of total RNAbyuse of an iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA) according to themanufacturer’s instructions. For real-time
PCR (RT-PCR), synthesized cDNA and iQ SYBR green Supermix were
run on aMyIQ real-timePCR system (Bio-Rad)with the following primer
pairs: for Map4k4, 5=-CATCTCCAGGGAAATCCTCAGG-3= and 5=-TT
CTGTAGTCGTAAGTGGCGTCTG-3=; and for Myf5, 5=-TATGAAGGC
TCCTGTATCCC-3= and 5=-ACGTGCTCCTCATCGTCTG-3=. 36B4 was
used as an internal loading control. Relative gene expression was deter-
mined using the CT method (27).
Statistics. The statistical significance of differences in the means of
experimental groups was determined by two-tailed Student’s t test,
using Microsoft Excel. The data are presented as means 	 standard
errors of the means (SEM). A P value of 
0.05 was considered signif-
icant.
RESULTS
Map4k4 expression and protein kinase activity are decreased
during skeletal muscle differentiation. To determine whether
Map4k4 may play a role in muscle differentiation, we first exam-
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ined Map4k4 expression in primary mouse satellite cells and ma-
ture muscle fibers. Adult satellite cells are considered to be pro-
genitor cells of somitic origin in skeletalmuscle development (28).
RT-PCR analysis revealed a 4-fold decrease inMap4k4 expression
in mouse quadriceps compared with that in purified satellite cells
isolated from the samemice via fluorescence-activated cell sorting
(Fig. 1A). We also investigated Map4k4 expression during differ-
entiation of C2C12 cells, a well-established cell line that is derived
frommouse satellite cells and faithfullymimics the skeletalmuscle
differentiation process in vitro. A reduction of Map4k4 protein
levels during C2C12 myogenic differentiation was detected by
Western blotting, concomitant with increased expression of the
differentiation markers myogenin and MyHC (Fig. 1B). Further-
more, wemeasuredMap4k4 protein kinase activity during C2C12
cell differentiation and determined that it was highest in confluent
myoblasts and decreased dramatically after 24 h of differentiation
(Fig. 1C). These results indicate that Map4k4 is dynamically reg-
ulated during skeletal muscle differentiation, suggesting a poten-
tial role for Map4k4 in muscle development.
Map4k4 silencing promotes skeletal muscle differentiation.
To explore the function of Map4k4 in myogenic differentiation,
we used siRNA directed against Map4k4 to deplete the protein
kinase in C2C12 myoblasts and monitored morphological differ-
ences during cell differentiation. Map4k4 silencing resulted in a
significant sustained reduction of Map4k4 protein throughout
differentiation and formation of largermyotubes after 48 h inDM
(Fig. 2A). Enhanced muscle cell fusion was observed in Map4k4-
silenced cells on differentiation day 3, as there was a shift toward
myotubes containingmore nuclei permyotube (Fig. 2B) and hav-
ing an increased fusion index (Fig. 2C). Map4k4 silencing also
resulted in a 70% increase of cell diameter in day 3myotubes (Fig.
2D), likely due to enhanced myoblast fusion. In addition, myo-
blast proliferation was not affected by Map4k4 depletion, as indi-
cated by similar nuclear numbers in random microscopic fields
and no change in the percentage of 5-ethynyl-2=-deoxyuridine
(EdU)-positive cells following a 1-h pulse when Map4k4 was si-
lenced in myoblasts (data not shown). These data exclude the
possibility that the hypernucleated myotubes with increased size
resulted from an increased number of undifferentiated myoblasts
available for the fusion process.
We further studied the differentiation program by examining
the expression of muscle differentiation markers. No significant
changes inMyoDprotein levels were detected inMap4k4-silenced
FIG 1 Expression and kinase catalytic activity ofMap4k4 during skeletal mus-
cle differentiation. (A) RT-PCR analysis of Map4k4 expression in isolated
mouse satellite cells versus quadriceps. Data represent means	 SEM for three
independent experiments. (B) Expression ofMap4k4 during C2C12myogenic
differentiation. Densitometry results are representative of means 	 SEM for
four independent experiments. (C) C2C12 myoblasts were incubated in DM
for the indicated times. Map4k4 kinase activity at each time point was assessed
by kinase assay and immunoblotting. Results represent means	 SEM. *, P

0.05; **, P
 0.01; ***, P
 0.001.
FIG 2 Map4k4 silencing promotesmyotube formation in C2C12 cells. C2C12
myoblasts were transfected with scrambled siRNA or siRNA against Map4k4.
Twenty-four hours later, the cells were transferred to DM for the indicated
times. (A) (Top) Efficiency of Map4k4 knockdown as determined by immu-
noblotting. (Bottom) Cells were fixed and immunostained for MyHC, and
myoblast differentiation was observed by fluorescence microscopy (green,
MyHC; blue, DAPI). Magnification,100. Data are representative of at least
three independent experiments. (B) Fractions of myotubes with the indicated
numbers of nuclei were quantified among 100 randomly chosen myotubes
after 72 h inDM. (C) The fusion index for day 3myotubes was calculated from
the ratio of the number of nuclei in MyHC-positive myotubes to the total
number of nuclei in one field for five randommicroscopic fields. (D)Myotube
diameters were measured with day 3 myotubes. Results represent means and
SEM for three independent experiments. ***, P
 0.001.
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cells compared with scrambled siRNA-transfected controls dur-
ing differentiation (Fig. 3A and B). However, significant transient
increases in myogenin and Mef2C expression were detected in
Map4k4-silenced cells at 16 h and 48 h of differentiation, respec-
tively (Fig. 3A and B). MyHC expression starts in a population of
mononuclear myoblasts and rapidly increases with myoblast fu-
sion during late myogenesis (29) (Fig. 2A). Map4k4 silencing en-
hanced MyHC expression during late C2C12 cell differentiation,
although the increase was only significant at 48 h of differentia-
tion, with trends toward increased expression at later time points
(Fig. 3A andB).MCKactivity, a latermarker of skeletalmuscle cell
differentiation, was increased by 45% in Map4k4-silenced cells at
day 3 of differentiation. These results suggest that silencing of
Map4k4 enhances myotube formation and promotes skeletal
myogenic differentiation.
Inhibition of myogenic differentiation by Map4k4 requires
its kinase activity. Since suppression of Map4k4 expression en-
hanced skeletal muscle differentiation, we hypothesized that
Map4k4 overexpression would have the opposite effect. To test
this, adenoviruses expressing aGFP control (AdGFP) orwild-type
(wt) Map4k4 (AdMap4k4 wt) (30) were used to infect C2C12
myoblasts for 18 h prior to differentiation. Overexpression of wt
Map4k4 impeded MyHC-positive myotube formation (Fig. 4A)
and myoblast fusion (Fig. 4B) within 72 h of serum deprivation.
Western blot analysis confirmed that the expression of Mef2c and
the late myogenic differentiation marker MyHC was inhibited in
wt Map4k4-overexpressing cells (Fig. 4C). We also assessed the
effect of a Map4k4 kinase-inactive mutant on myogenic differen-
tiation. C2C12 myoblasts were infected with adenoviruses ex-
pressing Map4k4 D152N, a kinase-inactive mutant of Map4k4
(AdMap4k4 D152N) (30), and were induced to differentiate into
myotubes for 72 h. Interestingly, Map4k4 D152N overexpression
caused the formation of larger myotubes and a substantial in-
crease in myoblast fusion (Fig. 4A and B), similar to the results of
theMap4k4 knockdown experiments (Fig. 2A andC). An increase
in Mef2c and MyHC expression was also observed in Map4k4
D152N-overexpressing cells (Fig. 4C). These data suggest that the
Map4k4 kinase-inactivemutant functions as a dominant-negative
FIG3 Map4k4 silencing enhances C2C12myogenic differentiation. C2C12myoblasts were transfectedwith scrambled orMap4k4 siRNA. Cells were transferred
toDM24h after transfection and differentiated for the indicated times. (A) Expression ofmyogenic differentiation proteinswas assayed by immunoblottingwith
the indicated antibodies. Data are representative of three independent experiments. (B) Densitometric analysis of the Western blots in panel A. (C) Creatine
kinase (CK) activities of transfected cells were measured after 3 days in DM. Data represent means	 SEM for three independent experiments. A.U, absorbance
units. *, P
 0.05; ***, P
 0.001.
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inhibitor, possibly by competing with functional endogenous
Map4k4 in C2C12 cells, and that Map4k4 kinase activity is re-
quired to repress skeletal muscle differentiation.
Map4k4 does not regulatemyogenic differentiation through
canonical MAPK signaling pathways. In other systems, Map4k4
has been described as an upstream effector in JNK, ERK, and p38
signaling pathways. These pathways are also reportedly involved
in skeletal muscle differentiation, and thus it seemed possible that
Map4k4 regulates myogenic differentiation through these canon-
ical MAPK pathways. To assess this hypothesis, we used siRNA to
suppress MAPK expression separately or in combination in
C2C12 myoblasts and monitored myogenic differentiation by vi-
sualizing MyHC-positive myotube formation. We posited that if
Map4k4 functions upstream in the respective signaling pathway to
regulate myogenesis, then silencing of the downstream effectors
would result in a phenotype similar to that withMap4k4 silencing.
However, depletion of p38 abolished myogenic differentiation
because few p38-silenced cells fused intomultinuclearmyotubes
(Fig. 5A), consistent with the conclusion derived from previous
studies that p38 is critical for skeletal myogenesis (31–33). Other
reports have shown that basal JNK activity is essential for regula-
tion of skeletal muscle differentiation and that inhibition of JNK
activation inhibits myogenesis by inducing myoblast apoptosis
(34). We suppressed JNK1 expression in myoblasts and observed
a minimal effect of JNK1 silencing on myotube formation under
our experimental conditions. However, JNK2 or JNK1/2 silencing
in combination inhibited myogenic differentiation, as shown by
reducedmyotube formation (Fig. 5A). Erk1/2 is essential formyo-
blast proliferation and is inhibitory to early differentiation, but it
is also required for myocyte fusion. Inhibition of ERK activity
early in myogenesis promotes differentiation, whereas later inhi-
bition impedes differentiation (32). In our study, Erk1 silencing in
C2C12 myoblasts promoted myotube formation, while knock-
down of Erk2 resulted in the formation of smaller myotubes.
Myotubes differentiated from Erk1 and Erk2 double-knockdown
myoblasts had a modestly decreased size compared to those dif-
ferentiated from the scrambled siRNA-transfected control cells
(Fig. 5A). These results revealed thatMap4k4 functions differently
on myogenic differentiation than the canonical MAPK pathways.
This conclusion was further confirmed by measurement of phos-
phorylation levels of theMAPKs during differentiation.No signif-
icant changes in p38, ERK1/2, or JNK1/2 phosphorylation were
observed in Map4k4-silenced cells (Fig. 5B) or C2C12 cells over-
expressing kinase-inactive Map4k4 D152N (data not shown), in-
dicating that Map4k4 failed to regulate their activities during
myogenic differentiation.
Map4k4 functions mainly at the early stage of myogenic dif-
ferentiation. To investigate the stages of myogenic differentiation
in which Map4k4 functions, C2C12 cells were transfected with
scrambled siRNAor siRNA targetingMap4k4 atmultiple stages of
differentiation and for various periods (Fig. 6A, right panels), and
myotube formation was assessed on day 4 after initiation of dif-
ferentiation by measuring the fusion index. In these experiments,
90% of Map4k4 proteins were depleted in myotubes on day 4 in
response to transfections of Map4k4 siRNA at the different time
points shown (Fig. 6B). Map4k4 silencing in myoblasts (day1)
provoked themost robust myotube formation (Fig. 6A, upper left
panels), as the fusion index in Map4k4-silenced cells was 60%
higher than that in the control cells on day 4 (Fig. 6C). Map4k4
depletion on day 1 in myocytes that were about to enter the late
stage of differentiation still resulted in larger myotubes and in-
creased myoblast fusion compared to those in the control cells.
However, the promotion of myotube formation was less than that
resulting fromMap4k4 silencing at earlier stages in myoblast dif-
ferentiation (Fig. 6A, middle left panels, and C). When siRNA
against Map4k4 was transfected into day 2 myotubes, coincident
with the onset of terminal differentiation, the myotubes showed
even smaller changes in size or fusion than the results obtained
fromMap4k4 suppression in myoblasts and day 1 myocytes (Fig.
6A, lower left panels, and C). These results indicate that Map4k4
functions in multiple stages of muscle differentiation but that the
enhanced myotube formation observed in Map4k4-depleted cells
at later stages of differentiation results mainly from a role that
Map4k4 plays at the onset ofmyogenic differentiation. The obser-
vation thatMap4k4 apparently plays an early role in the process is
also consistent with the higher Map4k4 kinase activity at the early
stage of muscle differentiation (Fig. 1B).
Map4k4 regulates myogenic differentiation in a Myf5-de-
pendent manner. Among the four myogenic regulatory factors,
Myf5 and MyoD regulate the early stage of skeletal muscle differ-
entiation. Because no change inMyoD expression was detected in
Map4k4-silenced cells during differentiation (Fig. 3A and B), we
examined Myf5 expression by RT-PCR and Western blotting. In
cells treated with scrambled siRNA, Myf5 expression increased in
early differentiation, peaked at 24 h, and then decreased (Fig. 7A
and B). Map4k4 silencing increased Myf5 mRNA transcripts 1.4-
fold within 16 h of myogenic differentiation (Fig. 7A). More dra-
matically, a 3-fold increase in Myf5 protein levels was detected in
FIG4 Map4k4 kinase activity is required for its inhibition of C2C12myogenic
differentiation. C2C12 myoblasts were infected with adenoviruses expressing
GFP, wild-type Map4k4, or a Map4k4 kinase-inactive D152N mutant and
differentiated for 72 h. (A) Cells were immunostained with anti-MyHC anti-
body. Images were photographed by fluorescence microscopy (red, MyHC;
blue, DAPI).Magnification,100. (B)Quantitative analysis ofmyogenic con-
version as scored by the fusion index. Data represent means and SEM for two
independent experiments. ***, P 
 0.001. (C) Immunoblot analysis of
Map4k4 and myogenic markers. Data are representative of three independent
experiments.
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Map4k4-depleted undifferentiatedmyoblasts andmyocytes at the
early stage of differentiation (Fig. 7B).
To determine whether the increase in Myf5 protein levels is
essential for the enhanced myogenic differentiation that is found
afterMap4k4 depletion, we performeddouble-knockdown exper-
iments to suppress Map4k4 and Myf5 expression simultaneously
in C2C12myoblasts and examined differentiation bymicroscopic
analysis and Western blotting. As expected, Map4k4 knockdown
promoted myogenic differentiation andMyf5 expression (Fig. 8).
In contrast, Myf5 silencing impeded myogenic differentiation, as
shown by reduced myotube formation (Fig. 8A), decreased myo-
blast fusion (Fig. 8B), and less expression of myogenin, Mef2C,
and MyHC during differentiation (Fig. 8C). Importantly, com-
paredwithMap4k4 suppression alone, smallermyotubes with less
fusion and myogenic differentiation factor expression were ob-
servedwhenMap4k4 andMyf5were silenced simultaneously (Fig.
8), indicating that reduced levels of Myf5 expression partially in-
hibit the effects of Map4k4 silencing on myogenic differentiation.
To further demonstrate that Myf5 is a downstream effector of
Map4k4 signaling in the regulation of skeletal muscle differentia-
tion, we overexpressed Map4k4 and Myf5 simultaneously in
C2C12 myoblasts and examined muscle differentiation by mi-
croscopy and immunoblotting. Expression of nativeMap4k4 pro-
tein kinase inhibited C2C12myogenic differentiation, whileMyf5
expression robustly enhancedmyotube formation (Fig. 9A and B)
and late differentiationmarker expression (Fig. 9C). Interestingly,
Myf5 expression significantly reversed the inhibitory effect of
Map4k4 expression inmyogenic differentiation (Fig. 9). Based on
these results, we concluded that Map4k4 regulates skeletal myo-
genesis at least partially by regulating Myf5 expression.
FIG 5 Map4k4 silencing does not promote skeletal muscle differentiation through canonicalMAPK signaling pathways. C2C12myoblasts were transfected with
scrambled siRNA or siRNA against Map4k4, p38, JNK1, JNK2, JNK1 and JNK2, Erk1, Erk2, or Erk1 and Erk2. Cells were transferred to DM 24 h after
differentiation and then incubated for 72 h. (A) (Left) Myoblast differentiation was observed by immunostaining for MyHC expression. Magnification, 50.
(Right) Efficiency ofMAP kinase knockdown as determined byWestern blotting. (B) C2C12myoblasts were transfected with scrambled orMap4k4 siRNA. Cells
were transferred to DM 24 h after transfection and then incubated for the indicated times. Lysates were immunoblotted with the indicated antibodies.
Densitometric analysis data represent means	 SEM for three independent experiments.
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DISCUSSION
In this study, we demonstrated that Map4k4 negatively regulates
C2C12 myogenic differentiation through a Myf5-dependent
mechanism. RNAi-mediated gene-specific silencing of Map4k4
expression or expression of a Map4k4 kinase-inactive mutant en-
hanced the differentiation of C2C12 myoblasts (Fig. 2, 3, and 4),
while Map4k4 expression inhibited this process (Fig. 4). Map4k4
suppression resulted in a significant increase inMyf5 expression at
the early stage of differentiation (Fig. 7). Furthermore, silencing of
Myf5 inhibited C2C12 myoblast differentiation and also sup-
pressed the ability of Map4k4 silencing to enhance myotube for-
mation (Fig. 8). In contrast, Myf5 expression promoted myotube
formation and reversed Map4k4-mediated myogenic differentia-
tion inhibition (Fig. 9), suggesting that Map4k4 regulates C2C12
myogenesis at least in part through Myf5.
We found that Map4k4 does not likely suppress myogenic dif-
ferentiation via activation of the canonical MAPK signaling path-
ways, although it has been reported thatMap4k4 can act upstream
of p38, JNK, and ERK. In contrast to the dramatic enhancement of
myotube formation upon Map4k4 silencing, a slight increase of
myotube formation was observed in Erk1-silenced cells, while
suppression of other MAPKs resulted in either no morphological
difference or smaller myotubes. In addition, no change in levels of
phosphorylatedMAPKs was observed uponMap4k4 knockdown,
which further suggests that the Map4k4 silencing-mediated in-
crease in myogenesis is independent of MAPKs (Fig. 5). These
findings implicating signaling pathways distinct from canonical
MAP kinase cascades are consistent with our studies of Map4k4
signaling in other cellular contexts. We have previously shown
that Map4k4 functions to mediate lipopolysaccharide (LPS)-in-
duced TNF- expression in macrophages, in a MAP kinase-inde-
pendent manner. In that study, silencing of macrophage Map4k4
had no effect on the phosphorylation of p38, ERK1/2, JNK1/2, or
their substrate ATF2 or c-Jun in response to LPS (35). These find-
ings strongly suggest that Map4k4 may regulate cellular processes
independently of MAPK signaling pathways.
In the current study, Myf5 expression was enhanced at the
early stage of myogenic differentiation in Map4k4-depleted myo-
cytes (Fig. 7). We further found that Myf5 is critical for myogenic
differentiation, because siRNA-mediated Myf5 suppression sig-
nificantly inhibited C2C12 myoblast differentiation (Fig. 8), con-
sistent with the observations reported in a recently published
study (36). Furthermore, we found that silencing ofMyf5 reduced
FIG6 Map4k4 functionsmainly at the early stage ofmyogenic differentiation.
C2C12 myoblasts were transfected with scrambled or Map4k4 siRNA at dif-
ferent stages of differentiation for the indicated times. (A) (Left) Cells were
fixed and immunostained for MyHC (green) after 4 days in DM. Magnifica-
tion, 100. (Right) Schematics of time courses of siRNA application. (B)
Efficiency of Map4k4 knockdown as determined by immunoblotting. (C) The
fusion index was calculated by dividing the number of nuclei inMHC-positive
cells by the total number of nuclei in that field. Data representmeans and SEM
for two independent experiments. **, P
 0.01; ***, P
 0.001.
FIG 7 Map4k4 silencing increases protein levels of Myf5. (A) C2C12 myo-
blasts were transfected with scrambled orMap4k4 siRNA and then transferred
toDM for the indicated times at 24 h posttransfection. (B) (Top)Myf5 expres-
sion determined by immunoblotting. (Bottom) Densitometry of Myf5 nor-
malized to -tubulin. Data are presented as means	 SEM for three indepen-
dent experiments. *, P
 0.05; **, P
 0.01.
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the enhancedmyotube formation that ensued uponMap4k4 sup-
pression to the same level as that with the scrambled siRNA con-
trol (Fig. 8), indicating that Map4k4 regulates myogenic differen-
tiation in aMyf5-dependent manner. Themarked rescue byMyf5
overexpression of myogenic differentiation inhibition because of
Map4k4 in myoblasts demonstrates that Map4k4 regulates skele-
tal muscle differentiation by acting upstream of Myf5. Other reg-
ulators may also be involved in the regulation of myogenesis by
Map4k4, such as proteins related to the myoblast fusion that oc-
curs in late differentiation. This concept is supported by the obser-
vation that Map4k4 suppression during late differentiation still sig-
nificantly increasedmyotube formation (Fig. 6A, middle panels).
We observed a modest increase in Myf5 mRNA (1.4-fold)
but an abundant increase (3-fold) in Myf5 protein in Map4k4-
silenced myocytes. The discrepancy in alteration levels between
Myf5mRNAandprotein suggests the possibility of a regulation by
Map4k4 of Myf5 at the translational or posttranslational level.
Mammalian target of rapamycin (mTOR) is a major regulator of
cell proliferation, survival, and growth via modulating protein
synthesis (37). It was reported that Map4k4 silencing in cultured
adipocytes promoted PPAR translation and global protein syn-
thesis via the activation of the mTOR signaling pathway (23).
However, Map4k4 silencing in C2C12 myoblasts had no detect-
able effect on the mTOR signaling pathway during myogenic dif-
ferentiation, as determined by unaltered phosphorylation of the
mTOR downstream effectors p70S6K and 4EBP1 (data not
shown).Moreover,Map4k4 suppression did not enhance insulin-
like growth factor (IGF)/Akt/mTOR signaling in IGF1-treated
C2C12myoblasts comparedwith scrambled siRNA controls (data
not shown). These results suggest that Map4k4 may not be a reg-
ulator of the mTOR signaling pathway in skeletal muscle. How-
ever, Map4k4 may regulate Myf5 translation in a protein-specific
manner during early myogenic differentiation, a concept that re-
quires further investigation. Besides enhanced translation, the in-
creased Myf5 protein content could also be because of reduced
protein degradation. However, we could not detect a difference in
Myf5 protein stability in Map4k4-silenced myoblasts compared
with controls (data not shown). In addition,Myf5 has been shown
to be activated by phosphorylation at serine49 and serine133 by
casein kinase 2 (CK2) in vitro (38). Thus, Map4k4 may regulate
Myf5 transcriptional activity through modulation of CK2 signaling
ordirectMyf5phosphorylationatother sites to regulate skeletalmus-
cle differentiation. Further studies are required to assess these hy-
potheses.
In human skeletal muscle, Map4K4 silencing protected against
TNF--mediated insulin resistance by preventing activation of
JNK1/2 and ERK1/2 (24). TNF- has been demonstrated to in-
hibit skeletal muscle differentiation in several studies (39–41).
Therefore, Map4k4 may mediate in part the inhibitory effect of
TNF- on C2C12 differentiation. When C2C12 myoblasts were
FIG 8 Suppression of Myf5 impairs Map4k4 silencing-enhanced myogenic differentiation. C2C12 myoblasts were transfected with scrambled siRNA or with siRNA
against Map4k4, Myf5, or a combination of both. (A) Cells were fixed and immunostained for MyHC (green) and DAPI (blue) at day 3 after differentiation, and
myogenic conversionwas observed by fluorescencemicroscopy.Magnification,50 (top) and100 (bottom). (B)The fusion indexwas calculated for transfected cells
after 3 days in DM. Results representmeans and SEM for three independent experiments. ***, P
 0.001. (C) Immunoblots ofmyogenic differentiation proteins. Data
are representative of three independent experiments.
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differentiated with DM containing 5 ng/ml of TNF- for 3 days,
we observed a marked inhibition of myotube formation, dramat-
ically reduced myogenic MyHC gene expression (10-fold), and
increased phosphorylation of JNK1/2. However, silencing of
Map4k4 inTNF--treated cells onlymarginally rescued the inhib-
itory effect of TNF- on C2C12 cell differentiation, as demon-
strated by a slight increase in myotube formation and MyHC ex-
pression (1.9-fold), with no significant alteration in JNK1/2
phosphorylation (data not shown). The fact that the silencing was
not complete in these studies makes data interpretation difficult,
and cells fromMap4k4 knockout mice will be required to address
whether Map4k4 plays a role in TNF--mediated inhibition of
myogenic differentiation.
The negative effect of Map4k4 onmyoblast fusion suggests a po-
tential involvement ofMap4k4 in skeletalmuscle regeneration.Mus-
cle regeneration is a rapid and extensive self-renewal process relying
on the presence of satellite cells, a population of quiescent, mononu-
cleated stem cells that are resident in adult skeletal muscle (42, 43).
Upon work overload or injury, satellite cells are activated and then
proliferate and differentiate into myoblasts that either fuse to each
other to create newmyofibers or fuse to existing damagedmyofibers
for repair. The fusion process in regeneration shares similar features
tomuscle cell fusion inmyogenic differentiation. BecauseMap4k4 is
abundantly present in satellite cells (Fig. 1) and is able to regulate
myoblast fusion in C2C12 differentiation, it may also suppress the
fusion process in muscle regeneration. Moreover, we showed here
that Map4k4 silencing in C2C12 myoblasts substantially increased
Myf5 expression during early myogenic differentiation (Fig. 6). In
muscle regeneration, satellite cell activation is associated with Myf5
upregulation (44), andMyf5 null mice had a significant delay in the
regenerative process (45). These studies supportMap4k4 as a poten-
tial regulator in skeletal muscle regeneration by regulating Myf5 ex-
pression and fusion in satellite cells.
In summary, the results of this study reveal a novel role for
Map4k4 in skeletal myogenesis and identifyMyf5 as a protein that is
regulated byMap4k4 tomediatemyogenic differentiation.Given the
effects that Map4k4 exerts on fusion and Myf5 expression, Map4k4
inhibition may enhance the regenerative capacity of damaged mus-
cles in trauma and degenerative diseases such as muscular dystro-
phies. The hypertrophic myotube formation induced by Map4k4
suppressionalso suggests thatMap4k4maybeanattractive therapeu-
tic target for the treatment of cachexia or sarcopenia. Further inves-
tigation into otherMap4k4 effectors that are involved inmyogenesis,
especially muscle-specific Map4k4 substrates, will be necessary to
fully understand the role ofMap4k4 as a new signaling node inmus-
cle development and function.
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